Search - tctmd.com

Displaying 361 - 380 of 400

Sort: Relevancy | Date

Presentation

Case 4: Patient with Atrial Fibrillation and DES

Presenter: Roxana Mehran

October 29, 2013

Presentation TCT 2013

Acute Coronary Syndrome and Atrial Fibrillation: 1 + 1 = 5

Presenter: C. Michael Gibson

October 29, 2013

Presentation TCT 2013

A Cost Benefit Analysis of Left Atrial Appendage Closure Versus Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: Vivek Y. Reddy

October 29, 2013

Presentation TCT 2013

Case Presentation: LAA Exclusion in a Patient With Atrial Fibrillation

Presenter: Evgeny Merkulov

October 28, 2013

Presentation TCT 2013

Stroke, Bleeding and Risk Scores in Atrial Fibrillation (with and without Anticoagulation)

Presenter: Stefan Bertog

October 27, 2013

Presentation TCT 2013

Multicenter Experience with the ACP for Stroke Prevention in Atrial Fibrillation

Presenter: Apostolos Tzikas

October 27, 2013

Presentation TCT 2013

Management of Patients with Atrial Fibrillation and Stents

Presenter: Neal Kleiman

October 27, 2013

Presentation TCT 2013

LAA Closure in Valvular Atrial Fibrillation (and TAVR Patients): Rationale and Results

Presenter: Samir Kapadia

October 27, 2013

Presentation Scripps 2013

Left Atrial Appendage Closure for Atrial Fibrillation: Current Status

Presenter: Matthew J. Price

October 03, 2013

Presentation ESC 2013

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Presenter: Alvaro Avezum

September 03, 2013

Presentation

Atrial Fibrillation in MI Patients: Impact on Health Care Utilization

Presenter: A.M. Chamberlain

August 27, 2013

Presentation

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

Presenter: David Garcia

August 05, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

Presentation

Risks and Benefits of Anticoagulation in Atrial Fibrillation

Presenter: MW Cullen

June 20, 2013

Presentation TVT 2013

Predictors of TAVR: Associated Strokes: New Onset Atrial Fibrillation, Postdilatation, and Others

Presenter: Josep Rodes-Cabau

June 12, 2013

Presentation Fellows 2013

LAA Closure for Nonvalvular Atrial Fibrillation

Presenter: Mark Reisman

April 17, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Presentation ECHO 2013

Advanced TEE: Clinical Decision Making in Cryptogenic Stroke and Atrial Fibrillation

Presenter: Marco R. Di Tullio

April 04, 2013

Presentation ACC 2013

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Presenter: David R. Holmes, Jr.

March 08, 2013

Presentation TCT 2013

Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial

Presenter: A. Rene, Philippe Genereux, Michael Ezekowitz, Ajay Kirtane, Roxana Mehran, Gregg Stone

January 31, 2013

Advertisement

Case 4: Patient with Atrial Fibrillation and DES

Acute Coronary Syndrome and Atrial Fibrillation: 1 + 1 = 5

A Cost Benefit Analysis of Left Atrial Appendage Closure Versus Warfarin for Stroke Prevention in Atrial Fibrillation

Case Presentation: LAA Exclusion in a Patient With Atrial Fibrillation

Stroke, Bleeding and Risk Scores in Atrial Fibrillation (with and without Anticoagulation)

Multicenter Experience with the ACP for Stroke Prevention in Atrial Fibrillation

Management of Patients with Atrial Fibrillation and Stents

LAA Closure in Valvular Atrial Fibrillation (and TAVR Patients): Rationale and Results

Left Atrial Appendage Closure for Atrial Fibrillation: Current Status

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Atrial Fibrillation in MI Patients: Impact on Health Care Utilization

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Risks and Benefits of Anticoagulation in Atrial Fibrillation

Predictors of TAVR: Associated Strokes: New Onset Atrial Fibrillation, Postdilatation, and Others

LAA Closure for Nonvalvular Atrial Fibrillation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Advanced TEE: Clinical Decision Making in Cryptogenic Stroke and Atrial Fibrillation

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content